Imexpharm

The story of Imexpharm begins in 1977 in Vietnam's Dong Thap province, established as a state-owned enterprise known as Level II Pharmaceutical Company. The early vision was guided by a team of dedicated pharmacists, including Tran Thi Dao, who would later become the company's General Director. Their focus from the outset was on producing quality pharmaceuticals, laying the groundwork for future growth. A pivotal moment arrived in July 2001, when the company was equitized, officially becoming Imexpharm Pharmaceutical JSC and marking its transition from a state-run entity to a corporation. This shift allowed for greater operational flexibility and a stronger focus on market-driven strategy. The company distinguished itself by investing heavily in technology and quality, becoming the first in Vietnam to achieve GMP-ASEAN standards and later securing the most EU-GMP certified production lines in the country. The next major chapter unfolded with foreign investment. In 2020, South Korean conglomerate SK Group acquired a significant 25% stake, becoming a strategic shareholder. This partnership injected new capital and international expertise. Over the next few years, SK Group increased its holdings, eventually reaching a controlling interest of approximately 65% by 2023. This period saw Imexpharm solidify its position as a manufacturing partner for global pharmaceutical giants. Most recently, the company entered another transformative phase. In 2025, reports confirmed that SK Group was divesting its entire stake to Chinese pharmaceutical giant Livzon Group, signaling a new strategic direction for Imexpharm as it continues its journey in the competitive global pharmaceutical landscape.